Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 2/20 | 0.30 |
| ▸ | CES1 | P23141 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17704771 | 0.82 | CHRM1 (0.36) | TDP1FFAR3ALDH1A1CHRM1 | |
| SCHEMBL13645801 | 0.79 | CES1 (0.52) | FFAR3ALDH1A1CES2CES1 | |
| SCHEMBL28089025 | 0.78 | ALDH1A1 (0.35) | TDP1FFAR3ALDH1A1CHRM1 | |
| SCHEMBL11986377 | 0.77 | — | — | |
| SCHEMBL2321266 | 0.77 | — | — | |
| SCHEMBL14269727 | 0.74 | ALDH1A1 (0.36) | ALDH1A1CHRM1 | |
| SCHEMBL209469 | 0.74 | — | — | |
| SCHEMBL2566126 | 0.74 | LMNA (0.42) | TDP1FFAR3ALDH1A1CHRM1CES2 | |
| SCHEMBL18211201 | 0.74 | — | — | |
| SCHEMBL27898440 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3283079-A1 | TARGETED TREATMENT OF LEIOMYOSARCOMA | Eli Lilly and Company (US) | 2018-02-21 | — | — | EP | disclosed |
| US-20170266161-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR MAKING THE SAME | SIGNUM BIOSCIENCES, INC. (US) | 2017-09-21 | — | — | US | disclosed |
| US-9486441-B2 | Compounds, compositions and methods for making the same | SIGNUM BIOSCIENCES, INC. (US) | 2016-11-08 | — | — | US | disclosed |
| WO-2016168014-A1 | TARGETED TREATMENT OF LEIOMYOSARCOMA | ELI LILLY AND COMPANY (US) | 2016-10-20 | — | — | WO | disclosed |
| WO-2014068388-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2014-05-08 | — | — | WO | disclosed |
| US-20090264496-A1 | Compounds, Compositions and Methods for Making the Same | SIGNUM BIOSCIENCES, INC. | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264496-A1 | Compounds, Compositions and Methods for Making the Same | PPP2CA, PPP4C, PPP6C | TDP1 727/4885FFAR3 4594/4885ALDH1A1 3385/4885 |
| US-20170266161-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR MAKING THE SAME | PPP2CA, PPP4C, PPP6C | TDP1 727/4885FFAR3 4594/4885ALDH1A1 3385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.